Return to Home Page
Home  |  Contact Us  |  About Cerus  |  Site Map  |  Search:

 

 

Webinar: Role of Pathogen Inactivation in Preparedness for Pandemic H1N1 and Emerging Pathogens

Webinar Replay

Program Description

This webinar looks at the impact that the H1N1 pandemic is likely to have on blood center operations and how pathogen inactivation could provide needed flexibility with regard to platelet and plasma availability.

As concerns continue to grow over the H1N1 Pandemic, so do the concerns over the supply blood components.  Availability and wastage, issues in every day operations, are even more of an operational challenge during such a crisis.  In this webinar, we address the latest global donor deferral policies on H1N1 and how large blood services have implemented pandemic preparedness plans.

Topics covered...

  • The measures taken by blood services globally to secure the blood supply in advance of the influenza season
  • Pandemic preparedness planning at both the state and national level
  • Challenges to blood center operations resulting from the H1N1 pandemic
  • How pathogen inactivation can provide increased confidence and flexibility with regard to maintaining platelet and plasma availability
  • The need to plan for emerging threats in the same way as planning for pandemic flu
  • The currently available pathogen inactivation strategies and their broad applicability

Speaker Bios

richardbenjamin

Richard Benjamin, MD, PhD
Chief Medical Officer
American Red Cross

Dr. Richard Benjamin is Chief Medical Officer of the American Red Cross in Washington, D.C. He received Transfusion Medicine and Pathology training at the Brigham and Women’s Hospital, Boston and obtained his PhD at Cambridge University, England in Immunology and post-doctoral research at Stanford University, CA. Dr. Benjamin is Board Member and Regional Director for North America for the International Society of Blood Transfusion, as well as an active member of the AABB. He also serves as the Adjunct Associate Professor of Pathology at Georgetown University, Washington, D.C. and is the author of more than 70 peer-reviewed publications.
carlhanson

Carl Hanson, PhD
Research Scientist Supervisor II
California Department of Public Health

Dr. Carl Hanson directs the Retroviral Diagnostics Section of the Viral and Rickettsial Disease Laboratory (VRDL) of the State of California Department of Public Health. Dr. Hanson originally trained in biophysics, became involved in virology in the 1970’s by applying a method of photochemical inactivation to the development of killed whole viral vaccines. Since then, he has been involved in HIV virology and immunology research since the beginning of the AIDS pandemic. He has chaired a committee on humoral immune responses for the International AIDS Vaccine Initiative (IAVI), and serves as principal investigator on various research programs. Dr. Hanson is a member of the International AIDS society (IAS), American Society for Microbiology, and the Pan American Group for Rapid Viral Diagnosis.

Return to webinar schedulearrow

 
© Cerus Corporation. All Rights Reserved.

Use of the INTERCEPT Blood System in the United States is limited by Federal law to investigational use. If you are a resident of the U.S., please click here.

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma.
Legal Info  |   Privacy Policy